



## MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

# Medical Policy

## Isolated Small Bowel Transplant

### Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

### Policy Number: 631

BCBSA Reference Number: 7.03.04

NCD/LCD: National Coverage Determination (NCD) for Intestinal and Multi-Visceral Transplantation (260.5)

### Related Policies

Small Bowel-Liver and Multivisceral Transplant, #[632](#)

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

A small bowel transplant using a cadaveric intestine may be **MEDICALLY NECESSARY** in adult and pediatric patients to treat the following conditions:

- Intestinal failure (characterized by loss of absorption and the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance), **AND**
- Established long-term dependency on total parenteral nutrition (TPN), **AND**
- Developing or have developed severe complications due to (TPN).

A small bowel transplant using a living donor may be **MEDICALLY NECESSARY** only when a cadaveric intestine is **NOT** available for transplantation in a patient who meets the criteria noted above for cadaveric intestinal transplant.

A small bowel retransplant may be **MEDICALLY NECESSARY** after a failed primary small bowel transplant.

A small bowel transplant using living donors is **NOT MEDICALLY NECESSARY** in all other situations.

A small bowel transplant in adult patients with intestinal failure who are able to tolerate TPN is **INVESTIGATIONAL**.

In addition to the above information, we do not cover small bowel transplant transplantation when any of the following conditions are present:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
  - Note: the assessment of risk of recurrence for a previously treated malignancy is made by the transplant team; providers must submit a statement with an explanation of why the patient with a recently treated malignancy is an appropriate candidate for a transplant.
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage disease not attributed to intestinal failure
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.

## Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Medical necessity criteria and coding guidance can be found through the link(s) below.

[National Coverage Determinations \(NCDs\)](#)

National Coverage Determination (NCD) for Intestinal and Multi-Visceral Transplantation (260.5)

**Note:** To review the specific NCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

## Prior Authorization Information

### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
<b>Commercial Managed Care (HMO and POS)</b>	This procedure is performed in the inpatient setting.
<b>Commercial PPO and Indemnity</b>	This procedure is performed in the inpatient setting.
<b>Medicare HMO Blue<sup>SM</sup></b>	This procedure is performed in the inpatient setting.
<b>Medicare PPO Blue<sup>SM</sup></b>	This procedure is performed in the inpatient setting.

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

### CPT Codes

CPT diagnosis codes:	Code Description
44135	Intestinal allotransplantation; from <i>cadaver</i> donor
44136	Intestinal allotransplantation; from <i>living</i> donor

## ICD-10 Procedure Coding

ICD-10-PCS Procedure codes:	Code Description
0DY80Z0	Transplantation of Small Intestine, Allogeneic, Open Approach
0DY80Z1	Transplantation of Small Intestine, Syngeneic, Open Approach

### Description

Solid organ transplantation offers a treatment option for patients with different types of end stage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life.<sup>1</sup> Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by the Organ Procurement and Transplantation Network (OPTN) and United Network of Organ Sharing (UNOS).

### Short Bowel Syndrome

Short bowel syndrome is a condition in which the absorbing surface of the small intestine is inadequate due to extensive disease or surgical removal of a large portion of the small intestine. The spectrum of clinical disease is widely variable from only single micronutrient malabsorption to complete intestinal failure, defined as the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes.<sup>2</sup> In adults, etiologies of short bowel syndrome include ischemia, trauma, volvulus, and tumors. In children, gastroschisis, volvulus, necrotizing enterocolitis, and congenital atresia are predominant causes. Although the actual prevalence of short bowel syndrome is not clear primarily due to under-reporting and a lack of reliable patient databases, its prevalence is estimated to be 30 cases per million in the U.S.<sup>2</sup>

### Treatment

The small intestine, particularly the ileum, can adapt to some functions of the diseased or removed portion over a period of 1 to 2 years. Prognosis for recovery depends on the degree and location of small intestine damage. Therapy focuses on achieving adequate macro- and micronutrient uptake in the remaining small bowel. Pharmacologic agents have been studied to increase villous proliferation and slow transit times, and surgical techniques have been advocated to optimize remaining small bowel.

However, some patients with short bowel syndrome are unable to obtain adequate nutrition from enteral feeding and become chronically dependent on total parenteral nutrition (TPN). For patients with short bowel syndrome, the rate of parenteral nutrition dependency at 1, 2, and 5 years has been reported to be 74%, 64%, and 48%, respectively.<sup>2</sup> Patients with complications from TPN may be considered candidates for a small bowel transplant. Complications include catheter-related mechanical problems, infections, hepatobiliary disease, and metabolic bone disease. While cadaveric intestinal transplant is the most commonly performed transplant, there has been a recent interest in using living donors.

Intestinal transplants (including multivisceral and bowel/liver) represent a small minority of all solid organ transplants. In 2018, 104 intestinal transplants were performed in the U.S. (59% of which were intestine-liver transplants).<sup>3</sup> Overall, both the number of new patients added to the intestinal transplant waiting list (n=135) and the number of intestinal transplants performed declined to their lowest levels in 2018.

### Summary

A small bowel transplant may be performed as an isolated procedure or in conjunction with other visceral organs, including the liver, duodenum, jejunum, ileum, pancreas, or colon. Isolated small bowel transplant is commonly performed in patients with short bowel syndrome. Small bowel/liver transplants and multivisceral transplants are considered in medical policy #632.

For individuals who have intestinal failure who receive a small bowel transplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Small bowel transplant is infrequently performed, and only relatively small case series, generally single-center, are available. Risks after small bowel transplant are high, particularly related to infection, but may be balanced against the need to avoid the long-term complications of total parenteral nutrition dependence. In addition, early small bowel transplant may obviate the need for a later combined liver/small bowel transplant. Transplantation is contraindicated in patients in whom the procedure is expected to be futile due to comorbid disease or in whom posttransplantation care is expected to worsen comorbid conditions significantly. Guidelines and U.S. federal policy no longer view HIV infection as an absolute contraindication for solid organ transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have failed small bowel transplant without contraindication(s) for retransplant who receive a small bowel retransplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Data from a small number of patients undergoing retransplantation are available. Although limited in quantity, the available data have suggested a reasonably high survival rate after small bowel retransplantation in patients who continue to meet criteria for transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Based on clinical input, obtained in 2009, small bowel transplantation using a living donor may be considered medically necessary only when a cadaveric intestinal transplant is not available. Routine use of living donor intestinal transplants is considered not medically necessary because the net health outcome associated with this procedure is reduced (compared with a cadaveric transplant) due to donor-related morbidity.

## Policy History

Date	Action
10/2020	BCBSA National medical policy review. Description, summary, and references updated. Policy statements unchanged.
10/2019	BCBSA National medical policy review. Description, summary, and references updated. Policy statements unchanged.
10/2018	BCBSA National medical policy review. No changes to policy statements. New references added. Background and summary clarified.
9/2017	New references added from BCBSA National medical policy.
7/2015	New references added from BCBSA National medical policy.
10/2014	Medical policy remediation: New indications for non-coverage. Clarified coding information. Effective 10/1/2014.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
5/2014	BCBSA National medical policy review. New medically necessary indications described. Effective 5/1/2014.
1/2014	New references added from BCBSA National medical policy.
12/2013	Removed ICD-9 diagnosis code as the policy requires prior authorization.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements
5/2012	BCBSA National medical policy review. Changes to policy statements.
11/2010	Reviewed - Medical Policy Group - Gastroenterology, Nutrition, Organ Transplantation. No changes to policy statements.
10/2010	BCBSA National medical policy review. No changes to policy statements.
6/2010	BCBSA National medical policy review. Changes to policy statements.
11/2009	BCBSA National medical policy review. Changes to policy statements.
11/2009	Reviewed - Medical Policy Group - Gastroenterology, Nutrition, Organ Transplantation. No changes to policy statements.

5/2009	BCBSA National medical policy review. No changes to policy statements.
11/2008	Reviewed - Medical Policy Group - Gastroenterology, Nutrition, Organ Transplantation. No changes to policy statements.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21 st century. *Ann Transl Med.* Oct 2018; 6(20): 409. PMID 30498736
2. Massironi S, Cavalcoli F, Rausa E, et al. Understanding short bowel syndrome: Current status and future perspectives. *Dig Liver Dis.* Mar 2020; 52(3): 253-261. PMID 31892505
3. U. S. Department of Health and Human Services (DHHS). Organ Procurement and Transplantation Network National Data. 2020; <https://optn.transplant.hrsa.gov/data/>. Accessed June 22, 2020
4. Sudan D. The current state of intestine transplantation: indications, techniques, outcomes and challenges. *Am J Transplant.* Sep 2014; 14(9): 1976-84. PMID 25307033
5. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Small bowel transplant. TEC Assessments. 1995;Volume 10:Tab 27.
6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Small bowel transplants in adults and multivisceral transplants. TEC Assessments. 1999;Volume 14:Tab 9.
7. Ueno T, Wada M, Hoshino K, et al. Impact of intestinal transplantation for intestinal failure in Japan. *Transplant Proc.* Jul-Aug 2014; 46(6): 2122-4. PMID 25131121
8. Benedetti E, Holterman M, Asolati M, et al. Living related segmental bowel transplantation: from experimental to standardized procedure. *Ann Surg.* Nov 2006; 244(5): 694-9. PMID 17060761
9. Sudan D. Long-term outcomes and quality of life after intestine transplantation. *Curr Opin Organ Transplant.* Jun 2010; 15(3): 357-60. PMID 20445450
10. Lacaille F, Irtan S, Dupic L, et al. Twenty-eight years of intestinal transplantation in Paris: experience of the oldest European center. *Transpl Int.* Feb 2017; 30(2): 178-186. PMID 27889929
11. Garcia Aroz S, Tzvetanov I, Hetterman EA, et al. Long-term outcomes of living-related small intestinal transplantation in children: A single-center experience. *Pediatr Transplant.* Jun 2017; 21(4). PMID 28295952
12. Dore M, Junco PT, Andres AM, et al. Surgical Rehabilitation Techniques in Children with Poor Prognosis Short Bowel Syndrome. *Eur J Pediatr Surg.* Feb 2016; 26(1): 112-6. PMID 26535775
13. Rutter CS, Amin I, Russell NK, et al. Adult Intestinal and Multivisceral Transplantation: Experience From a Single Center in the United Kingdom. *Transplant Proc.* Mar 2016; 48(2): 468-72. PMID 27109980
14. Lauro A, Zanfi C, Dazzi A, et al. Disease-related intestinal transplant in adults: results from a single center. *Transplant Proc.* Jan-Feb 2014; 46(1): 245-8. PMID 24507060
15. Matarese LE, Costa G, Bond G, et al. Therapeutic efficacy of intestinal and multivisceral transplantation: survival and nutrition outcome. *Nutr Clin Pract.* Oct 2007; 22(5): 474-81. PMID 17906271
16. Vianna RM, Mangus RS, Tector AJ. Current status of small bowel and multivisceral transplantation. *Adv Surg.* 2008; 42: 129-50. PMID 18953814
17. Wu GS, Cruz RJ, Cai JC. Acute antibody-mediated rejection after intestinal transplantation. *World J Transplant.* Dec 24 2016; 6(4): 719-728. PMID 28058223
18. Florescu DF, Qiu F, Langnas AN, et al. Bloodstream infections during the first year after pediatric small bowel transplantation. *Pediatr Infect Dis J.* Jul 2012; 31(7): 700-4. PMID 22466325
19. Florescu DF, Langnas AN, Grant W, et al. Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients. *Pediatr Transplant.* May 2012; 16(3): 294-301. PMID 22212495

20. Florescu DF, Islam KM, Grant W, et al. Incidence and outcome of fungal infections in pediatric small bowel transplant recipients. *Transpl Infect Dis.* Dec 2010; 12(6): 497-504. PMID 20626710
21. Calvo Pulido J, Jimenez Romero C, Morales Ruiz E, et al. Renal failure associated with intestinal transplantation: our experience in Spain. *Transplant Proc.* Jul-Aug 2014; 46(6): 2140-2. PMID 25131125
22. Boyer O, Noto C, De Serre NP, et al. Renal function and histology in children after small bowel transplantation. *Pediatr Transplant.* Feb 2013; 17(1): 65-72. PMID 22882667
23. Fujimoto Y, Uemoto S, Inomata Y, et al. Living-related small bowel transplant: management of rejection and infection. *Transplant Proc.* Feb 1998; 30(1): 149. PMID 9474986
24. Gruessner RW, Sharp HL. Living-related intestinal transplantation: first report of a standardized surgical technique. *Transplantation.* Dec 15 1997; 64(11): 1605-7. PMID 9415566
25. Jaffe BM, Beck R, Flint L, et al. Living-related small bowel transplantation in adults: a report of two patients. *Transplant Proc.* May 1997; 29(3): 1851-2. PMID 9142299
26. Tesi R, Beck R, Lambiase L, et al. Living-related small-bowel transplantation: donor evaluation and outcome. *Transplant Proc.* Feb-Mar 1997; 29(1-2): 686-7. PMID 9123480
27. Colfax G. HIV Organ Policy Equity (HOPE) Act Is Now Law. 2013; <https://obamawhitehouse.archives.gov/blog/2013/11/21/hiv-organ-policy-equity-hope-act-now-law>. Accessed June 22, 2020.
28. United Network for Organ Sharing (UNOS). OPTN policies, procedures implemented to support HOPE Act. 2015; <http://www.unos.org/optn-policies-procedures-implemented-to-support-hope-act/>. Accessed June 22, 2020
29. Organ Procurement and Transplantation Network (OPTN). Organ Procurement and Transplantation Network Policies. 2020; [https://optn.transplant.hrsa.gov/media/1200/optn\\_policies.pdf](https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf). Accessed June 22, 2020.
30. Working Party of the British Transplantation Society. *Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised).* British Transplantation Society Guidelines Macclesfield, UK: British Transplantation Society; 2017.
31. Desai CS, Khan KM, Gruessner AC, et al. Intestinal retransplantation: analysis of Organ Procurement and Transplantation Network database. *Transplantation.* Jan 15 2012; 93(1): 120-5. PMID 22113492
32. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. *Ann Surg.* Oct 2009; 250(4): 567-81. PMID 19730240
33. American Gastroenterological Association. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. *Gastroenterology.* Apr 2003; 124(4): 1105-10. PMID 12671903
34. Kaufman SS, Atkinson JB, Bianchi A, et al. Indications for pediatric intestinal transplantation: a position paper of the American Society of Transplantation. *Pediatr Transplant.* Apr 2001; 5(2): 80-7. PMID 11328544
35. Centers for Medicare and Medicaid Services. National Coverage Determination for Intestinal and Multi-visceral Transplantation (260.5). 2006; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=280&ncdver=2&DocID=260.5&SearchType=Advanced&bc=IAAAABAAAA&>. Accessed June 22, 2020